Literature DB >> 19339718

Safe drugs and the cost of good intentions.

Hans-Georg Eichler1, Eric Abadie, June M Raine, Tomas Salmonson.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19339718     DOI： 10.1056/NEJMp0900092

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

1.  New horizons in pharmaceutical regulation.

Authors:  Alasdair Breckenridge; Michelle Mello; Bruce M Psaty
Journal:  Nat Rev Drug Discov       Date:  2012-06-29       Impact factor: 84.694

2.  Risk Management Plans: are they a tool for improving drug safety?

Authors:  Serena Frau; Maria Font Pous; Maria Rosa Luppino; Anita Conforti
Journal:  Eur J Clin Pharmacol       Date:  2010-06-25       Impact factor: 2.953

3.  Physicians' perceptions of the definition of major bleeding in major orthopedic surgery: results of an international survey.

Authors:  Enrique Ginzburg; Franck Dujardin
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

Review 4.  Today's challenges in pharmacovigilance: what can we learn from epoetins?

Authors:  Hans C Ebbers; Aukje K Mantel-Teeuwisse; Ellen H M Moors; Huub Schellekens; Hubert G Leufkens
Journal:  Drug Saf       Date:  2011-04-01       Impact factor: 5.606

5.  Safety of psychotropic medicines: contribution from observational evidence.

Authors:  H Verdoux
Journal:  Epidemiol Psychiatr Sci       Date:  2018-05-30       Impact factor: 6.892

6.  A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.

Authors:  Minette-Joëlle Zeukeng; Enrique Seoane-Vazquez; Pascal Bonnabry
Journal:  Eur J Clin Pharmacol       Date:  2018-02-22       Impact factor: 2.953

Review 7.  Assessment of benefits and risks in development of targeted therapies for cancer--The view of regulatory authorities.

Authors:  Francesco Pignatti; Bertil Jonsson; Gideon Blumenthal; Robert Justice
Journal:  Mol Oncol       Date:  2014-10-16       Impact factor: 6.603

8.  Off-label prescribing: a call for heightened professional and government oversight.

Authors:  Rebecca Dresser; Joel Frader
Journal:  J Law Med Ethics       Date:  2009       Impact factor: 1.718

9.  Adverse Drug Event Discovery Using Biomedical Literature: A Big Data Neural Network Adventure.

Authors:  Ahmad P Tafti; Jonathan Badger; Eric LaRose; Ehsan Shirzadi; Andrea Mahnke; John Mayer; Zhan Ye; David Page; Peggy Peissig
Journal:  JMIR Med Inform       Date:  2017-12-08

10.  Number of patients studied prior to approval of new medicines: a database analysis.

Authors:  Ruben G Duijnhoven; Sabine M J M Straus; June M Raine; Anthonius de Boer; Arno W Hoes; Marie L De Bruin
Journal:  PLoS Med       Date:  2013-03-19       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.